ArticleJournal of virology2026
A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses.
Donglan Liu, Yuxuan Zhang, Min Zhang, Raoqing Guo, Wanwan Peng, Ren Cao, Xiaoyun Yang, Jiayan Chen, Si Huang, Jinwei Li and 2 more
Abstract read
In one paragraphArticle in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Donglan Liu *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-8342-7637 Yuxuan Zhang *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Min Zhang *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0002-3204-4553 Raoqing Guo *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wanwan PengSchool of Chemistry and Chemical Engineering, University of South China, Hengyang, China.
Ren CaoGuangzhou National Laboratory, Bio-island, Guangzhou, China.
Xiaoyun YangGuangzhou National Laboratory, Bio-island, Guangzhou, China.
Jiayan ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Si HuangGuangzhou Medical University, Guangzhou, China.
Jinwei LiGuangzhou Medical University, Guangzhou, China.
Chen ShengGuangzhou Medical University, Guangzhou, China.
Liuxing QinState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0008-0655-7877 Funding
Guangdong High-Level Talent Program 2025TQ09A487Major Project of Guangzhou National Laboratory GZNL2023A01009Major Project of Guangzhou National Laboratory SRPG22-001National Natural Science Foundation of China 82470003Postdoctoral Scientific Research Start-up Found of GuangzhouPrevention and Control of Emerging and Major Infection Diseases-National Science and Techology Major Project 2025ZD01999901Prevention and Control of Emerging and Major Infection Diseases-National Science and Techology Major Project 2026ZD01999704Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project 2025ZD01902100
6 · The paper itselfAbstract
Influenza viruses continue to pose a significant threat to human and animal health. However, the limited number of licensed antivirals is increasingly compromised by drug resistance driven by high mutation rates. This highlights the urgent need for broad-spectrum therapeutics with novel mechanisms of action. Nanobodies, a new generation of antibody drugs, have great potential in the treatment of influenza virus infections. Neuraminidase (NA) mediates the sialic acid cleavage required for viral release, and its genetic drift is generally slower than that of hemagglutinin (HA) in influenza viruses, making it an attractive target for broad-spectrum antiviral and vaccine development. To construct a phage display nanobody library targeting NA, an alpaca was immunized with the NA protein of the H9N2 influenza virus. A specific nanobody, designated F4, was subsequently screened from the immune library. The nanobody was engineered into an Fc-fused nanobody, F4-Fc, which exhibited inhibitory activity against multiple influenza A and B viruses
Indexed as
Antiviral AgentsInfluenza A virusInfluenza B virusNeuraminidaseOrthomyxoviridae InfectionsSingle-Domain AntibodiesViral ProteinsAnimalsAntibodies, ViralCamelids, New WorldDogsHumansInfluenza A Virus, H9N2 SubtypeMiceAntibodies, ViralAntiviral AgentsNeuraminidaseSingle-Domain AntibodiesViral Proteinsantiviral mechanismsimmunotherapyinfluenza virusnanobodyneuraminidase
Identifiers
PMID42671552
PMCPMC13595958
What OpenQuestion holds
Textmetadata
Read underepoch 390